Skip to content

Eagle Pharmaceuticals, Inc.: filings

Every Eagle Pharmaceuticals, Inc. annual and quarterly report in the SEC record with the published financial measures it tagged, 38 filings, each linked to its SEC index.

Filing record ends 2023-08-09

The latest filing in this captured record is a 10-Q/A filed 2023-08-09. No later filing is in the SEC companyfacts record captured on 2026-09-22. Eagle Pharmaceuticals, Inc. may have stopped filing, merged, or changed its reporting entity; nothing on this page describes its current status. Values are as reported at the time.

Filings with published measures

Each page shows what one filing reported, as tagged in that filing, with the periods it covered. Later filings can restate a value; the company overview shows the latest-filed value per period.

FormFiledFiscal periodMeasuresFactsSEC accession
10-Q/A2023-08-09fiscal Q2 2023551500000827871-23-000024
10-Q2023-08-08fiscal Q2 2023551500000827871-23-000021
10-Q2023-05-09fiscal Q1 2023561140000827871-23-000016
10-K2023-03-23fiscal FY 2022571450000827871-23-000009
10-Q2022-11-09fiscal Q3 2022571540000827871-22-000027
10-Q2022-08-09fiscal Q2 2022571540000827871-22-000021
10-Q2022-05-09fiscal Q1 2022561140000827871-22-000017
10-K2022-03-08fiscal FY 2021571460000827871-22-000008
10-Q2021-11-09fiscal Q3 2021571520000827871-21-000029
10-Q2021-08-09fiscal Q2 2021571540000827871-21-000022
10-Q2021-05-10fiscal Q1 2021551120000827871-21-000016
10-K2021-03-05fiscal FY 2020541390000827871-21-000011
10-Q2020-11-02fiscal Q3 2020561520000827871-20-000028
10-Q2020-08-10fiscal Q2 2020551510000827871-20-000024
10-Q2020-05-11fiscal Q1 2020551140000827871-20-000014
10-K2020-03-02fiscal FY 2019531750000827871-20-000007
10-Q2019-11-12fiscal Q3 2019511360000827871-19-000026
10-Q2019-08-08fiscal Q2 2019511370000827871-19-000020
10-Q2019-05-07fiscal Q1 2019501010000827871-19-000013
10-K2019-02-28fiscal FY 2018481590000827871-19-000008
10-Q2018-11-01fiscal Q3 2018441210000827871-18-000010
10-Q2018-08-07fiscal Q2 2018451230000827871-18-000008
10-Q2018-05-10fiscal Q1 201843870000827871-18-000005
10-K2018-02-26fiscal FY 2017481500000827871-18-000003
10-Q2017-11-08fiscal Q3 2017401080000827871-17-000010
10-Q2017-08-09fiscal Q2 2017411100000827871-17-000007
10-Q2017-05-08fiscal Q1 201741840000827871-17-000004
10-K2017-03-15fiscal FY 2016501970000827871-17-000002
10-Q2016-11-09fiscal Q3 2016421160000827871-16-000080
10-Q2016-08-09fiscal Q2 2016421160000827871-16-000074
10-Q2016-05-10fiscal Q1 201642860000827871-16-000064
10-K2016-02-29fiscal FY 2015432000000827871-16-000049
10-Q2015-11-12fiscal Q3 2015381050000827871-15-000047
10-Q2015-08-11fiscal Q2 2015381050000827871-15-000042
10-Q2015-05-15fiscal Q1 201538780000827871-15-000031
10-K2014-12-22fiscal FY 2014391040000827871-14-000015
10-Q2014-08-11fiscal Q3 2014371000000827871-14-000013
10-Q2014-05-15fiscal Q2 201436980000827871-14-000010

Inspect the source

Entity
Eagle Pharmaceuticals, Inc. / CIK 0000827871
Captured
SEC response SHA-256
3e196e7045dfad3c93f68f1244dd5522d5a75ba4b717887654a1105750eb52b2

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0000827871.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))